Authors' objectives:
               Herpes zoster, which is commonly known as shingles, affects approximately one in three people that have had chickenpox. Shingles is typically recognised by a painful blistering rash on the torso. While vaccines against herpes zoster are licensed and marketed in Ireland, these vaccines are not included in the Health Service Executive (HSE) national immunisation schedule. The Department of Health requested that HIQA complete a health technology assessment (HTA) to inform a decision on the addition of shingles vaccination to the adult immunisation schedule. The protocol document outlines the evidence synthesis approach that HIQA’s evaluation team will use to complete this piece of work.